vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and LCNB CORP (LCNB). Click either name above to swap in a different company.
LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $18.7M, roughly 1.3× CytomX Therapeutics, Inc.). LCNB CORP runs the higher net margin — 23.7% vs -0.8%, a 24.5% gap on every dollar of revenue. On growth, LCNB CORP posted the faster year-over-year revenue change (5.1% vs -25.7%). LCNB CORP produced more free cash flow last quarter ($33.4M vs $-15.8M). Over the past eight quarters, LCNB CORP's revenue compounded faster (15.7% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.
CTMX vs LCNB — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $23.9M |
| Net Profit | $-154.0K | $5.7M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 29.2% |
| Net Margin | -0.8% | 23.7% |
| Revenue YoY | -25.7% | 5.1% |
| Net Profit YoY | 97.6% | -7.6% |
| EPS (diluted) | — | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $23.9M | ||
| Q3 25 | — | $23.8M | ||
| Q2 25 | $18.7M | $22.8M | ||
| Q1 25 | $50.9M | $21.5M | ||
| Q4 24 | $38.1M | $22.7M | ||
| Q3 24 | $33.4M | $21.4M | ||
| Q2 24 | $25.1M | $19.3M | ||
| Q1 24 | $41.5M | $17.8M |
| Q4 25 | — | $5.7M | ||
| Q3 25 | — | $6.9M | ||
| Q2 25 | $-154.0K | $5.9M | ||
| Q1 25 | $23.5M | $4.6M | ||
| Q4 24 | $18.9M | $6.1M | ||
| Q3 24 | $5.7M | $4.5M | ||
| Q2 24 | $-6.5M | $925.0K | ||
| Q1 24 | $13.8M | $1.9M |
| Q4 25 | — | 29.2% | ||
| Q3 25 | — | 35.6% | ||
| Q2 25 | -6.9% | 31.6% | ||
| Q1 25 | 44.4% | 25.6% | ||
| Q4 24 | 46.4% | 32.9% | ||
| Q3 24 | 12.3% | 24.9% | ||
| Q2 24 | -33.7% | 4.9% | ||
| Q1 24 | 28.1% | 12.5% |
| Q4 25 | — | 23.7% | ||
| Q3 25 | — | 29.1% | ||
| Q2 25 | -0.8% | 26.0% | ||
| Q1 25 | 46.2% | 21.4% | ||
| Q4 24 | 49.6% | 27.0% | ||
| Q3 24 | 17.2% | 21.2% | ||
| Q2 24 | -26.0% | 4.8% | ||
| Q1 24 | 33.3% | 10.7% |
| Q4 25 | — | $0.40 | ||
| Q3 25 | — | $0.49 | ||
| Q2 25 | — | $0.41 | ||
| Q1 25 | — | $0.33 | ||
| Q4 24 | — | $0.44 | ||
| Q3 24 | — | $0.31 | ||
| Q2 24 | — | $0.07 | ||
| Q1 24 | — | $0.15 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $21.6M |
| Total DebtLower is stronger | — | $104.4M |
| Stockholders' EquityBook value | $119.9M | $273.9M |
| Total Assets | $175.1M | $2.2B |
| Debt / EquityLower = less leverage | — | 0.38× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $21.6M | ||
| Q3 25 | — | $35.9M | ||
| Q2 25 | $49.0M | $49.8M | ||
| Q1 25 | $47.6M | $37.7M | ||
| Q4 24 | $38.1M | $35.7M | ||
| Q3 24 | $40.6M | $39.4M | ||
| Q2 24 | $43.2M | $34.9M | ||
| Q1 24 | $36.2M | $33.0M |
| Q4 25 | — | $104.4M | ||
| Q3 25 | — | $104.7M | ||
| Q2 25 | — | $105.0M | ||
| Q1 25 | — | $104.6M | ||
| Q4 24 | — | $155.2M | ||
| Q3 24 | — | $155.7M | ||
| Q2 24 | — | $162.2M | ||
| Q1 24 | — | $162.6M |
| Q4 25 | — | $273.9M | ||
| Q3 25 | — | $269.9M | ||
| Q2 25 | $119.9M | $263.5M | ||
| Q1 25 | $25.0M | $258.7M | ||
| Q4 24 | $-456.0K | $253.0M | ||
| Q3 24 | $-23.5M | $253.2M | ||
| Q2 24 | $-31.2M | $245.2M | ||
| Q1 24 | $-31.7M | $233.7M |
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | $175.1M | $2.3B | ||
| Q1 25 | $98.5M | $2.3B | ||
| Q4 24 | $120.5M | $2.3B | ||
| Q3 24 | $139.0M | $2.3B | ||
| Q2 24 | $159.2M | $2.4B | ||
| Q1 24 | $184.7M | $2.3B |
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.39× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.40× | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.66× | ||
| Q1 24 | — | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $34.4M |
| Free Cash FlowOCF − Capex | $-15.8M | $33.4M |
| FCF MarginFCF / Revenue | -84.6% | 140.2% |
| Capex IntensityCapex / Revenue | 0.1% | 4.0% |
| Cash ConversionOCF / Net Profit | — | 6.08× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $54.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $34.4M | ||
| Q3 25 | — | $14.0M | ||
| Q2 25 | $-15.8M | $5.5M | ||
| Q1 25 | $-21.0M | $2.2M | ||
| Q4 24 | $-19.9M | $93.2M | ||
| Q3 24 | $-20.7M | $11.9M | ||
| Q2 24 | $-19.5M | $54.9M | ||
| Q1 24 | $-26.0M | $-11.9M |
| Q4 25 | — | $33.4M | ||
| Q3 25 | — | $13.7M | ||
| Q2 25 | $-15.8M | $5.2M | ||
| Q1 25 | $-21.2M | $2.1M | ||
| Q4 24 | $-20.0M | $89.4M | ||
| Q3 24 | $-20.7M | $10.5M | ||
| Q2 24 | $-19.6M | $53.8M | ||
| Q1 24 | $-26.2M | $-12.8M |
| Q4 25 | — | 140.2% | ||
| Q3 25 | — | 57.4% | ||
| Q2 25 | -84.6% | 23.0% | ||
| Q1 25 | -41.6% | 10.0% | ||
| Q4 24 | -52.5% | 394.0% | ||
| Q3 24 | -62.1% | 49.0% | ||
| Q2 24 | -78.2% | 278.6% | ||
| Q1 24 | -63.1% | -71.8% |
| Q4 25 | — | 4.0% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 0.2% | 0.3% | ||
| Q4 24 | 0.2% | 16.7% | ||
| Q3 24 | 0.1% | 6.7% | ||
| Q2 24 | 0.4% | 5.9% | ||
| Q1 24 | 0.3% | 4.8% |
| Q4 25 | — | 6.08× | ||
| Q3 25 | — | 2.02× | ||
| Q2 25 | — | 0.92× | ||
| Q1 25 | -0.89× | 0.48× | ||
| Q4 24 | -1.05× | 15.23× | ||
| Q3 24 | -3.61× | 2.63× | ||
| Q2 24 | — | 59.35× | ||
| Q1 24 | -1.89× | -6.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
LCNB
Segment breakdown not available.
